Company / Shareholders' Equity
Matinas BioPharma Holdings, Inc. Shareholders' Equity History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$7.6M
FY2024
5-year range
$7.6M / $63.7M
FY2020-FY2024
Trend
-79.3%
vs FY2023
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $52M to $8M over the past 2 years.
Based on SEC 10-K filings.
$8M in FY2024 with a 5-year CAGR of -14.0%.
Declined from $52M to $8M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -47.5%
- 5-Year CAGR
- -14.0%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of -14.0%, indicating a declining trend.
- In FY2024, shareholders' equity decreased 79.3% year-over-year.
- Peak shareholders' equity was recorded in FY2020.
- Lowest shareholders' equity in the period was in FY2015.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -18.50 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $7.6M | -79.3% |
| FY2023 | $36.6M | -30.2% |
| FY2022 | $52.5M | +0.0% |
| FY2021 | $52.5M | -17.6% |
| FY2020 | $63.7M | +294.8% |
| FY2019 | $16.1M | +51.1% |
| FY2018 | $10.7M | +49.4% |
| FY2017 | $7.1M | +0.0% |
| FY2016 | $7.1M | +17.7% |
| FY2015 | $6.1M | - |
As of FY2024 · SEC 10-K · Updated Jun 24, 2026